Ataibeckley Inc. · NASDAQ:ATAI

Ataibeckley — ATAI Life Sciences — Merger or Acquisition (June 2025)

23 slides from Ataibeckley's merger presentation, Jun 3, 2025

  1. Slide 1: Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health

    atai Life Sciences Beckley Psytech to Combine Creating a Global Leader in Psychédeli Benes Mental Health A June 2,2025 “— © ¥Beckle (O) atal OPsytech

  2. Slide 2: Disclaimer

    Disclaimer All references in this presentation to “we”, “us”, “our”, “ atai”, or the “Company” refer to ATAI Life Sciences N.V. and its consolidated subsidiaries, unless the context otherwise requires. This presentation contains forward-looking stateme nts within the meaning of the private Securiti

  3. Slide 3: Stronger together, atai life sciences and Beckley Psytech unlock value for patients and shareholders

    3 Stronger together, atai life sciences and Beckley Psytech unlock value for patients and shareholders Experienced management team Fully owned pipeline with first-in-class potential Multiple near-term milestones Commercially scalable psychedelic therapies Strong IP portfolio Long-term financial syne

  4. Slide 4: atai-Beckley Business Combination Highlights

    1. Lock-up holders may not sell or transfer shares befor e the later of (a) 60 days following the public announcement of the Phase 2b study or (b) transaction closing (the “Lock-Up Period”). Upon the expiry of the Lock-Up Peri od lock-up holders shall cease to be restricted at a rate of 1/12th of ea

  5. Slide 5: Experienced management team with deep CNS, psychedelic and drug development expertise

    5 Anne Johnson, CPA Chief Financial Officer Rob Conley, M.D. Chief Research & Development Officer Gerd Kochendoerfer, Ph.D. Chief Operating Officer Experienced management team with deep CNS, psychedelic and drug development expertise Cosmo Feilding Mellen Co-founder and Chief Strategy Officer1 Glenn

  6. Slide 6: Combined vision delivered through a pipeline of fully-owned psychedelic development programs

    Combined vision is being delivered through a pipeline of fully-owned psychedelic development programs across a range of compounds and psychiatric indications Abbreviations: DMT = Dimethyltryptamine; R-MDMA = R enantiomer of 3,4-Methylened ioxymethamphetamine Programs Primary Indication Preclin Phase

  7. Slide 7: Fully funded through multiple near-term milestones

    Fully funded through multiple near-term milestones ACHIEVED AND ANTICIPATED UPCOMING MILESTONES1,2 Q2’25 Q1’25 Q3’25 Q4’25 Q1’26 Ph 2b (CIAS) data RL-007 Pro-cognitive neuromodulator Ph 2a (SAD) initiation Ph 2a (SAD) data EMP-01 R-MDMA Ph 2 (TRD) data Ph 2 (TRD) trial initiation ✓ VLS-01 DMT Ph 2b

  8. Slide 8: Market Opportunity and Unmet Need

    Market Opportunity and Unmet Need INTERVENTIONAL PSYCHIATRY

  9. Slide 9: SPRAVATO achieved blockbuster status in 2024 (>$1B)

    Leading interventional psychiatry treatment, SPRAVATO® (esketamine) for TRD, achieved blockbuster status in 2024 (>$1B) with ~86% of sales in the US 9 2-hour dosing protocol with established infrastructure Patients monitored for at least 2 hours at each treatment session Delivered intranasally under

  10. Slide 10: Novel psychedelic treatments

    DEVELOPED TO PROVIDE RAPID AND DURABLE EFFICACY WITH A SHORT TIME-IN-CLINIC Novel psychedelic treatments

  11. Slide 11: BPL-003 and VLS-01 are novel psychedelic candidates developed to optimize patient access for TRD

    BPL-003 and VLS-01 are novel psychedelic candidates developed to optimize patient access for TRD with a short time-in-clinic Abbreviations: TRD = Treatment Resistant Depression; IND = Investigational New Drug Application; COM = Com position of Matter 1. Dourron HM, Nichols CD, Simonsson O, Bradley M

  12. Slide 12: BPL-003 and VLS-01 designed to leverage SPRAVATO 2-hour in-clinic treatment paradigm

    BPL-003 and VLS-01 designed to leverage SPRAVATO® 2-hour in-clinic treatment paradigm in depression 12 0 4 8 12 ANTICIPATEDTIME TO DISCHARGE FROMCLINIC POST-DOSE 1 (inhours)Ilustrative SPRAVATO® BPL-003 Multi-dose Psilocybin 5-MeO- +analogs DMT MDMA LSD Average workday (8hours) ~2 ~2 ~2 ~1 to3* ~6 ~

  13. Slide 13: BPL-003: Intranasal Mebufotenin Benzoate for TRD & AUD

    INTRANASAL MEBUFOTENIN BENZOATE FOR TRD & AUD BUSINESS COMBINATION WITH BECKLEY PSYTECH BPL-003

  14. Slide 14: BPL-003 Phase 1 Results

    BPL-003 Phase 1 Results BPL-003 PHASE 1 RESULTS KEY TAKEAWAYS 30 25 20 15 10 5 0 0 2 4 6 8 10 PK/PD results demonstrated a dose proportional profile with perceptual effects generally resolving <90 minutes Pharmacokinetics (PK) Exposure was dose-proportional Rapid onset with mean Tmax of 6-17 min Mea

  15. Slide 15: BPL-003 Phase 2a Clinical Trial Design

    BPL-003 Completed Part 1 & Part 2 of the open-label Phase 2a study investigating BPL- 003 in patients with TRD Phase 2a Clinical Trial Design Key Inclusion Criteria: Montgomery-Asberg Depression Rating Scale (MADRS) score ≥24 Part 1 & 3: willing and able to discontinue current antidepressants Part 2

  16. Slide 16: BPL-003 Phase 2a Part 1 (Monotherapy Cohort) Data

    BPL-003 Phase 2a Part 1 (Monotherapy Cohort) Data MADRS SCORE OVER TIME BPL-003 10 MG SINGLE DOSE KEY TAKEAWAYS Mean MADRS reduction of ~13 points at Day 2, and sustained to Day 85 55% of patients met response criteria1 one day after a single 10mg dose of BPL-003 55% of patients met clinical remissi

  17. Slide 17: Initial data from the adjunctive/SSRI cohort broadly consistent with monotherapy

    Initial data from the adjunctive/SSRI cohort is broadly consistent with monotherapy data BPL-003 Phase 2a Part 2 (Adjunct to SSRIs) Initial Data MADRS SCORE OVER TIME BPL-003 SINGLE DOSE (ADJUNCTIVE) KEY TAKEAWAYS Participants with moderate-severe depression having failed 2 prior therapies and on a

  18. Slide 18: BPL-003 Phase 2a Part 1 & 2 Safety

    Drug Related TEAEs TOTALa N subjects (%) [N events]b Administration site discomfortc 10 (41.7%) [141#] Nausea 5 (20.8%) [51#] Vomiting 5 (20.8%) [55#] Other events (<10% frequency) 8 (33.3%) [83#, 1*] TOTAL 14 (58%) [32] BPL-003 Phase 2a Part 1 & 2 Safety DRUG RELATED TEAES KEY TAKEAWAYS 97% of even

  19. Slide 19: BPL-003 Phase 2b study in moderate to severe TRD patients

    BPL-003 BPL-003 randomized, quadruple-masked, monotherapy Phase 2b study in moderate to severe TRD patients Phase 2b Clinical Trial Design Key Inclusion Criteria: Patients with moderate to severe TRD Hamilton Depression Scale (HAM-D) >= 19 Willing and able to discontinue current antidepressants Key

  20. Slide 20: BPL-003 Strong IP portfolio with coverage out to 2043

    BPL-003 Strong IP portfolio with coverage out to 2043 20 BPL-003 has superior properties that are novel and non-obvious, compared to other salt forms Higher permeation, less irritation, greater stability, dose-proportional PK These novel and non-obvious properties have enabled us to build strong IP

  21. Slide 21: Summary + Q&A

    Summary + Q&A FY Beckley Oatai sie,

  22. Slide 22: Together, atai and Beckley Psytech will create impactful psychedelic treatments

    Together, atai Life Sciences and Beckley Psytech will create impactful psychedelic treatments addressing significant unmet needs in mental health 22 Short treatment time, patent-protected: BPL-003 potential to be a first-in- class mebufotenin benzoate therapy; and VLS-01, potential best-in-class rou

  23. Slide 23: Forward-looking Statements

    23 Forward-looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained

ATAI Life Sciences — Merger or Acquisition (June 2025) on 6ix